Efficacy and Safety in Retinal Vein Occlusion Treated with at Least Three Consecutive Intravitreal Dexamethasone Implants

Table 2

Mean (±SE) central retinal thickness before and after 3 consecutive injections of dexamethasone according to the occlusion type and previous therapy.

	Baseline	2 months after 3rd injection	Mean change (95% CI)
Overall	617 (26)	330 (34)	−282 (−342 to −220)	<0.001
Occlusion type
CRVO ()	648 (31)	325 (45)	−317 (−413 to −222)	<0.001	0.27
BRVO ()	568 (44)	339 (58)	−229 (−428 to −30)	0.033
Treatment-naïve eyes
No ()	642 (31)	382 (52)	−254 (−370 to −138)	0.001	0.41
Yes ()	577 (46)	261 (19)	−316 (−447 to −186)	0.001

CRVO: central retinal vein occlusion branch; BRVO: branch retinal vein occlusion branch.
Linear mixed regression analysis was used to estimate the mean change and to perform the between comparison.
Defined as first central retinal thickness values before 1st injection of dexamethasone.
for comparison between baseline and postinjection values.
for between-group comparison calculated by including interaction term between groups and time of measure in linear mixed model.